TrialCancer research and treatment2025

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study.

Yoon Seok Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.